Market Cap 12.25M
Revenue (ttm) 0.00
Net Income (ttm) -6.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 40,600
Avg Vol 388,622
Day's Range N/A - N/A
Shares Out 7.04M
Stochastic %K 47%
Beta 0.08
Analysts Strong Sell
Price Target $12.00

Company Profile

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phas...

Industry: Biotechnology
Sector: Healthcare
Phone: 289 800 9600
Address:
100 Spy Court, Markham, Canada
GeeJoon
GeeJoon Dec. 14 at 7:34 PM
$EDSA I'm not all against atm offer, but do they really have to make it every time the market cap is all time low? Last time they doubled the outstanding shares, the buyers already suffering 10% loss, and after 6 month you start nothing and tell us you are running out of cash, and smashing the sp by announcing those useless covid trial data after covid gone for 2 years?
0 · Reply
TheGhostOfEd
TheGhostOfEd Dec. 14 at 7:22 PM
$EDSA FWIW, this is the first time they've explicitly said anything like this: "...we are engaging with potential strategic and government partners to seek additional non-dilutive support and collaborative arrangements that advance our programs."
0 · Reply
TheGhostOfEd
TheGhostOfEd Dec. 14 at 7:09 PM
$IFRX $EDSA Speaking of general ARDS - IMO BARDA really missed the mark with the platform P2. It's not enough patients and there's simply not enough interest in it w/o being a registrational trial. The fact that they are dumping 120m to activate 60 sites into an "exploratory" P2....I mean what a waste. All that time on scale up and enrollment. The trial does (almost) nothing for sponsors, patients, or HHS, IMHO. It should have been designed to be adaptive in nature with a shared placebo arm - that would have resulted in a shorter trial run time and more patients getting the IPs. Furthermore, each drug should be able to graduate into a registrational P3. Ffs, 2 of the 3 drugs in the trial already have some level of supporting lifesaving data and cause agnostic MoAs. The only thing about the BARDA trial that would pique my interest would be the announcement of a follow on P3, but I feel like there's some adage about government work I should be throwing in here...
0 · Reply
TheGhostOfEd
TheGhostOfEd Dec. 14 at 6:49 PM
$EDSA Blank, redacted is literally Edesa to the t Fucking assholes
0 · Reply
TheGhostOfEd
TheGhostOfEd Dec. 14 at 6:48 PM
$EDSA More lies, evidently! LOL
0 · Reply
TheGhostOfEd
TheGhostOfEd Dec. 14 at 6:18 PM
$EDSA It looks like in Q3 they drew down around another 250k in contributions from the grant. The grant was amended on the last day of the quarter so remains to be seen if the updated scope will allow them to more aggressively use that funding, guess we'll find that out in February at some point.
0 · Reply
TheGhostOfEd
TheGhostOfEd Dec. 14 at 6:09 PM
$EDSA Is there any plausible "bullish" reason on why the updated SOW is now completely redacted? I have no doubt that Edesa is begging the Canadian govt for more financing/grants, remains to be seen if they cough it up, under what conditions, and exactly for what. At least they are finally sort of tacitly admitting that they are going to need some help; be it government or big pharma. On that note, I hope these bozos finally realize that going at the Vitiligo trial alone is a horrible idea. There has to be some level of interest. Partner prior to the P2, even if the economic terms aren't amazing, and refocus "efforts" elsewhere....mind you I quoted the word efforts because in reality they are just milking their salaries and defrauding investors and Canadian taxpayers, however that's already fairly well established. Re: CA govt...the real question is do they see through their fraudulent veneer and do they really see value in EB05...if so in what way are they going to contribute?
1 · Reply
TheGhostOfEd
TheGhostOfEd Dec. 14 at 4:05 AM
$EDSA this is edsa https://x.com/gurdeeppandher/status/1999862302611562596?s=46
0 · Reply
GeeJoon
GeeJoon Dec. 13 at 5:44 AM
$EDSA “Our strategy to advance a high-impact dermatology asset alongside a now-validated respiratory therapeutic is bearing fruit, and we believe Edesa is well positioned for our mission to deliver transformative therapies to patients with high unmet medical needs,” said Par Nijhawan, MD, Chief Executive Officer of Edesa. “With new momentum and data in hand, we are engaging with potential strategic and government partners to seek additional non-dilutive support and collaborative arrangements that advance our programs.”
0 · Reply
GeeJoon
GeeJoon Dec. 13 at 5:03 AM
$EDSA i think the best use of the velan investment is to withdraw the vitiligo trial, and let those money burnt slowly for running the company until BARDA P2 finishes
0 · Reply
Latest News on EDSA
Edesa Biotech Reports Fiscal Year 2025 Results

Dec 12, 2025, 4:20 PM EST - 1 day ago

Edesa Biotech Reports Fiscal Year 2025 Results


Edesa Biotech Announces Upcoming Conference Schedule

Oct 31, 2025, 4:30 PM EDT - 6 weeks ago

Edesa Biotech Announces Upcoming Conference Schedule


Edesa Biotech Posts Narrower Loss in Q3

Aug 8, 2025, 4:49 PM EDT - 4 months ago

Edesa Biotech Posts Narrower Loss in Q3


Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results

Aug 8, 2025, 4:35 PM EDT - 4 months ago

Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results


Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results

May 14, 2025, 4:15 PM EDT - 7 months ago

Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results


Edesa Biotech Announces Chief Financial Officer Transition

Apr 4, 2025, 4:15 PM EDT - 9 months ago

Edesa Biotech Announces Chief Financial Officer Transition


Edesa Biotech Reports Fiscal 1st Quarter 2025 Results

Feb 14, 2025, 4:15 PM EST - 10 months ago

Edesa Biotech Reports Fiscal 1st Quarter 2025 Results


Edesa Biotech Reports Fiscal Year 2024 Results

Dec 13, 2024, 4:30 PM EST - 1 year ago

Edesa Biotech Reports Fiscal Year 2024 Results


Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results

Aug 9, 2024, 4:20 PM EDT - 1 year ago

Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results


Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results

May 10, 2024, 4:15 PM EDT - 1 year ago

Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results


Edesa Biotech Reports Fiscal 1st Quarter 2024 Results

Feb 9, 2024, 4:15 PM EST - 2 years ago

Edesa Biotech Reports Fiscal 1st Quarter 2024 Results


Edesa Biotech Reports Fiscal Year 2023 Results

Dec 15, 2023, 4:10 PM EST - 2 years ago

Edesa Biotech Reports Fiscal Year 2023 Results


Edesa Biotech to Present at Dermatology Drug Development Summit

Oct 26, 2023, 4:05 PM EDT - 2 years ago

Edesa Biotech to Present at Dermatology Drug Development Summit


Edesa Biotech Announces One-for-Seven Reverse Share Split

Oct 10, 2023, 9:00 AM EDT - 2 years ago

Edesa Biotech Announces One-for-Seven Reverse Share Split


Edesa Biotech Reports Fiscal Third Quarter 2023 Results

Aug 9, 2023, 4:15 PM EDT - 2 years ago

Edesa Biotech Reports Fiscal Third Quarter 2023 Results


Edesa Biotech Appoints Biotech Deal Veteran to CFO Role

Jun 27, 2023, 8:15 AM EDT - 2 years ago

Edesa Biotech Appoints Biotech Deal Veteran to CFO Role


Edesa Biotech Anti-Inflammatory Drug Candidate Assigned Name

Jun 15, 2023, 8:00 AM EDT - 2 years ago

Edesa Biotech Anti-Inflammatory Drug Candidate Assigned Name


Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results

May 11, 2023, 4:30 PM EDT - 2 years ago

Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results


Edesa Biotech to Participate in Swiss Biotech Day

Apr 20, 2023, 8:30 AM EDT - 2 years ago

Edesa Biotech to Participate in Swiss Biotech Day


Edesa Biotech Reports Fiscal 1st Quarter 2023 Results

Feb 10, 2023, 9:00 AM EST - 3 years ago

Edesa Biotech Reports Fiscal 1st Quarter 2023 Results


FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate

Dec 20, 2022, 8:30 AM EST - 3 years ago

FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate


Edesa Biotech Reports Fiscal Year 2022 Results

Dec 16, 2022, 9:00 AM EST - 3 years ago

Edesa Biotech Reports Fiscal Year 2022 Results


GeeJoon
GeeJoon Dec. 14 at 7:34 PM
$EDSA I'm not all against atm offer, but do they really have to make it every time the market cap is all time low? Last time they doubled the outstanding shares, the buyers already suffering 10% loss, and after 6 month you start nothing and tell us you are running out of cash, and smashing the sp by announcing those useless covid trial data after covid gone for 2 years?
0 · Reply
TheGhostOfEd
TheGhostOfEd Dec. 14 at 7:22 PM
$EDSA FWIW, this is the first time they've explicitly said anything like this: "...we are engaging with potential strategic and government partners to seek additional non-dilutive support and collaborative arrangements that advance our programs."
0 · Reply
TheGhostOfEd
TheGhostOfEd Dec. 14 at 7:09 PM
$IFRX $EDSA Speaking of general ARDS - IMO BARDA really missed the mark with the platform P2. It's not enough patients and there's simply not enough interest in it w/o being a registrational trial. The fact that they are dumping 120m to activate 60 sites into an "exploratory" P2....I mean what a waste. All that time on scale up and enrollment. The trial does (almost) nothing for sponsors, patients, or HHS, IMHO. It should have been designed to be adaptive in nature with a shared placebo arm - that would have resulted in a shorter trial run time and more patients getting the IPs. Furthermore, each drug should be able to graduate into a registrational P3. Ffs, 2 of the 3 drugs in the trial already have some level of supporting lifesaving data and cause agnostic MoAs. The only thing about the BARDA trial that would pique my interest would be the announcement of a follow on P3, but I feel like there's some adage about government work I should be throwing in here...
0 · Reply
TheGhostOfEd
TheGhostOfEd Dec. 14 at 6:49 PM
$EDSA Blank, redacted is literally Edesa to the t Fucking assholes
0 · Reply
TheGhostOfEd
TheGhostOfEd Dec. 14 at 6:48 PM
$EDSA More lies, evidently! LOL
0 · Reply
TheGhostOfEd
TheGhostOfEd Dec. 14 at 6:18 PM
$EDSA It looks like in Q3 they drew down around another 250k in contributions from the grant. The grant was amended on the last day of the quarter so remains to be seen if the updated scope will allow them to more aggressively use that funding, guess we'll find that out in February at some point.
0 · Reply
TheGhostOfEd
TheGhostOfEd Dec. 14 at 6:09 PM
$EDSA Is there any plausible "bullish" reason on why the updated SOW is now completely redacted? I have no doubt that Edesa is begging the Canadian govt for more financing/grants, remains to be seen if they cough it up, under what conditions, and exactly for what. At least they are finally sort of tacitly admitting that they are going to need some help; be it government or big pharma. On that note, I hope these bozos finally realize that going at the Vitiligo trial alone is a horrible idea. There has to be some level of interest. Partner prior to the P2, even if the economic terms aren't amazing, and refocus "efforts" elsewhere....mind you I quoted the word efforts because in reality they are just milking their salaries and defrauding investors and Canadian taxpayers, however that's already fairly well established. Re: CA govt...the real question is do they see through their fraudulent veneer and do they really see value in EB05...if so in what way are they going to contribute?
1 · Reply
TheGhostOfEd
TheGhostOfEd Dec. 14 at 4:05 AM
$EDSA this is edsa https://x.com/gurdeeppandher/status/1999862302611562596?s=46
0 · Reply
GeeJoon
GeeJoon Dec. 13 at 5:44 AM
$EDSA “Our strategy to advance a high-impact dermatology asset alongside a now-validated respiratory therapeutic is bearing fruit, and we believe Edesa is well positioned for our mission to deliver transformative therapies to patients with high unmet medical needs,” said Par Nijhawan, MD, Chief Executive Officer of Edesa. “With new momentum and data in hand, we are engaging with potential strategic and government partners to seek additional non-dilutive support and collaborative arrangements that advance our programs.”
0 · Reply
GeeJoon
GeeJoon Dec. 13 at 5:03 AM
$EDSA i think the best use of the velan investment is to withdraw the vitiligo trial, and let those money burnt slowly for running the company until BARDA P2 finishes
0 · Reply
GeeJoon
GeeJoon Dec. 13 at 3:12 AM
$EDSA they spent all velan money to travels and accomodation for conference, also sponsor the stupid vitiligo day without any solid thing started
0 · Reply
TheGhostOfEd
TheGhostOfEd Dec. 13 at 1:53 AM
$EDSA Fuck this company. It's going to zero. I hope they all fucking die horrible deaths. Fuck them all to hell.
0 · Reply
TheGhostOfEd
TheGhostOfEd Dec. 12 at 11:28 PM
$EDSA New investment thesis just dropped: Hoping everyone at the company you invested in drops dead.
0 · Reply
AllPenniesNoDividends
AllPenniesNoDividends Dec. 12 at 10:30 PM
$EDSA This whole company is just reliant on the BARDA trial and has been for around a year. Anything else is just fluff unless we get a partnership IMO. Not sure how the EB05 agreement is written anymore, but if we are on a tight timeline before the EB05 gets FDA or equivalent approval in other countries, that would be very concerning. Take a $50-100m acquisition and put this company to bed once and for all
1 · Reply
TheGhostOfEd
TheGhostOfEd Dec. 12 at 10:25 PM
$EDSA and fuck that ni**a Gary....I hope they deport him to Canada
0 · Reply
TheGhostOfEd
TheGhostOfEd Dec. 12 at 10:23 PM
$EDSA Fuck all of them to death in their Canadian assholes.
0 · Reply
TheGhostOfEd
TheGhostOfEd Dec. 12 at 10:19 PM
$EDSA There isn't going to be a Vitiligo trial. We've been defrauded again. I hope they all drop dead.
0 · Reply
TheGhostOfEd
TheGhostOfEd Dec. 12 at 10:14 PM
$EDSA There really ain't much to say here....just far too many red flags and inaction. The company is composed of two bit scammers at the management level and incompetent dumbfucks underneath. Price target = $0. I can only pray that horrible, unspeakable things will eventually happen to all those involved in this fraud.
0 · Reply
TheGhostOfEd
TheGhostOfEd Dec. 12 at 10:11 PM
$EDSA Ye good olde redacted grant amendment lol
0 · Reply
TheGhostOfEd
TheGhostOfEd Dec. 12 at 10:03 PM
$EDSA They are already laying the groundwork to trash EB06. This is a scam, plain and simple.
0 · Reply
TheGhostOfEd
TheGhostOfEd Dec. 12 at 9:35 PM
$EDSA This company is an avoid for sure....they are full of shit. Zero progress.
0 · Reply
JohnTrack
JohnTrack Dec. 12 at 9:33 PM
$EDSA news ripple https://www.rapidticker.com/news/edsa-edesa-biotech-reports-fiscal-year-de0cf6
0 · Reply